TCT 2024’s Top TAVR Studies
CardiacWire
NOVEMBER 3, 2024
This year’s TCT conference saw a deluge of TAVR studies examining everything from the efficacy of valve designs to TAVR’s impact on aortic and tricuspid regurgitation. Patients who received early TAVR were 16% less likely to experience MACE and saw better heart function over a median of 3.8
Let's personalize your content